PubMed Health. A service of the National Library of Medicine, National Institutes of Health.
A.D.A.M. Medical Encyclopedia [Internet]. Atlanta (GA): A.D.A.M.; 2013.
A.D.A.M. Medical Encyclopedia.
Homocystinuria is an inherited disorder that affects the metabolism of the amino acid methionine.
Causes, incidence, and risk factors
Homocystinuria is inherited in families as an autosomal recessive trait. This means that the child must inherit the non-working gene from both parents to be seriously affected.
Homocystinuria has several features in common with Marfan syndrome. Unlike Marfan syndrome, in which the joints tend to be "loose," in homocystinuria the joints tend to be "tight."
Symptoms
Newborn infants appear healthy. Early symptoms, if present at all, are not obvious.
Symptoms may occur as mildly delayed development or failure to thrive. Increasing visual problems may lead to diagnosis of this condition.
Other symptoms include:
- Chest deformities (pectus carinatum, pectus excavatum)
- Flush across the cheeks
- Intellectual disability
- Long limbs
- Mental disorders
- Nearsightedness
- Spidery fingers (arachnodactyly)
- Tall, thin build
Signs and tests
The health care provider may notice that the child is tall and thin (Marfanoid).
Other signs include:
- Curved spine (scoliosis)
- Deformity of the chest
- Dislocated lens of the eye
If there is poor or double vision, an ophthalmologist should perform a dilated eye exam to look for dislocation of the lens or nearsightedness.
There may be a history of blood clots. Intellectual disability, slightly low IQ, or mental illness are common.
Tests:
- Amino acid screen of blood and urine
- Genetic testing
- Skeletal x-ray
- Skin biopsy with a fibroblast culture
Treatment
There is no cure for homocystinuria. However, just under half of people respond to high doses of vitamin B6 (also known as pyridoxine).
Those who do respond will need to take vitamin B6 supplements for the rest of their lives. Those who do not respond will need to eat a low-methionine diet. Most will need to be treated with trimethylglycine (a medication also known as betaine).
Neither a low-methionine diet nor medication will improve existing intellectual disability. Medication and diet should be closely supervised by a physician who has experience treating homocystinuria.
Taking a folic acid supplement and adding cysteine (an amino acid) to the diet are helpful.
Expectations (prognosis)
Although no cure exists for homocystinuria, vitamin B6 therapy can help about half of people affected by the condition.
If the diagnosis is made while a patient is young, starting a low methionine diet quickly can prevent some intellectual disability and other complications of the disease. For this reason, some states screen for homocystinuria in all newborns.
Patients whose blood homocysteine levels continue to rise are at increased risk for blood clots. Clots can cause serious medical problems and shorten lifespan.
Complications
Most serious complications result from blood clots. These episodes can be life threatening.
Dislocated lenses of the eyes can seriously damage vision. Lens replacement surgery should be considered.
Intellectual disability is a serious consequence of the disease. However, it can be reduced if diagnosed early.
Calling your health care provider
Call your health care provider if you or a family member shows symptoms of this disorder, especially if you have a family history of homocystinuria. Also call if you have a family history and are planning to have children.
Prevention
Genetic counseling is recommended for people with a family history of homocystinuria who want to have children. Intrauterine diagnosis of homocystinuria is available. This involves culturing amniotic cells or chorionic villi to test for cystathionine synthase (the enzyme that is missing in homocystinuria).
If there are known gene mutations in the parents or family, samples from chorionic villus sampling or amniocentesis can be used to test for these mutations.
References
- Rezvani I, Melvin JJ. Defects in metabolism of amino acids. In: Kliegman RM, Stanton BF, St. Geme J, Schor N, Behrman RE, eds. Nelson Textbook of Pediatrics. 19th ed. Philadelphia, Pa: Saunders Elsevier; 2011:chap 79.
Review Date: 2/2/2012.
Reviewed by: Chad Haldeman-Englert, MD, Wake Forest School of Medicine, Department of Pediatrics, Section on Medical Genetics, Winston-Salem, NC. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only — they do not constitute endorsementscof those other sites. © 1997–2011 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
Newborn screening for homocystinuria
Homocystinuria is a rare condition caused by mistakes in a gene that is responsible for making an enzyme called cystathionine beta synthase (CBS). People with homocystinuria have a deficiency of this enzyme and as a result have high levels of a substance called homocysteine in their bodies. Although such individuals appear normal at birth, over a period of months and years, they develop serious problems that effect eyesight, lead to delayed mental development, cause unhealthy bones, and have a high risk of having blood clots. Treatment with a special diet and medicines can prevent the development of these complications, but must be started very early in life to be truly effective. In some parts of the world homocystinuria has been tested for in newborn babies. The aim of this review was to identify and assess the results of any controlled clinical trials where homocystinuria was tested for in newborn infants, that would allow us to draw conclusions based on the highest level of evidence. No such trials were found. We know of some uncontrolled studies which suggest that newborn screening for homocystinuria and its early treatment are effective. Future long‐term research is needed to provide strong evidence for or against screening. This research may also show whether screening is cost effective.
Making smart health choicesDevelop the skills to assess health advice and make better-informed decisions about your health and managing illness.
- HomocystinuriaHomocystinuriaPubMed Health
Your browsing activity is empty.
Activity recording is turned off.
See more...